Immune Checkpoint Inhibitors in Organ Transplant Patients

医学 无容量 移植排斥反应 免疫系统 免疫检查点 器官移植 免疫疗法 人口 免疫学 细胞毒性T细胞 肿瘤科 移植 内科学 生物 体外 环境卫生 生物化学
作者
Adam S. Kittai,Hayden Oldham,Jeremy Paul Cetnar,Matthew Taylor
出处
期刊:Journal of Immunotherapy [Lippincott Williams & Wilkins]
卷期号:40 (7): 277-281 被引量:151
标识
DOI:10.1097/cji.0000000000000180
摘要

Modulation of T-cell activity through blockade of coinhibitory molecules has revolutionized the treatment of various malignancies. Several immune checkpoint inhibitors are currently Food and Drug Administration approved which target various coinhibitory pathways including cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), programmed death 1 receptor (PD-1), and programmed cell death ligand-1. Clinical trials that lead to the Food and Drug Administration approval of these agents often excluded patients with an organ transplant. Excluding these patients was deliberate due to concern that immune checkpoint inhibitor therapy could lead to graft rejection. The PD-1 and CTLA-4 pathways are essential to downregulate our immune system in the setting of T-cell activation to prevent autoimmunity. Furthermore, both pathways are implicated in transplanted organ tolerance and modulation of the pathways may inadvertently lead to peripheral transplant rejection. Currently, there are no guidelines for the treatment of patients with immune checkpoint inhibitors in the setting of a prior organ transplant. Thus far, there are only 10 reported cases of patients in the literature who were treated in this setting. Two additional cases are reported herein, including 1 patient with a prior cardiac transplant receiving nivolumab for non-small cell lung cancer. Of the 12 cases, 4 patients experienced organ rejection. From these observations, the authors hypothesize factors that affect safety and of this treatment modality in this patient population. These factors include the integral role of the PD-1 pathway compared with the CTLA-4 pathway in organ acceptance, sequential implementation of different immune checkpoint inhibitor classes, length of time with a transplant before therapy, strength of immunosuppressive agents to prevent organ transplant rejection, and immunogenicity of the particular organ grafted. Although limited cases have been reported, there are circumstances in which immune checkpoint inhibitors have been used in the setting of organ transplantation without resulting in organ rejection. A thorough discussion with the patient of the potential risks, including graft rejection, and benefits of this therapy is necessary before beginning this treatment. More research is needed to explore the safety and efficacy of immune checkpoint inhibitors in the setting of organ transplantation.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
WXD发布了新的文献求助10
1秒前
wzzzy发布了新的文献求助20
1秒前
ruanyousong完成签到,获得积分10
1秒前
2秒前
丘比特的应助被纯真问丝采纳,获得10
2秒前
Viiigo完成签到,获得积分10
2秒前
2秒前
科研通AI6.4的应助被笙笙采纳,获得10
2秒前
科研通AI6.4的应助被笙笙采纳,获得10
2秒前
万能图书馆的应助被笙笙采纳,获得10
3秒前
JamesPei的应助被笙笙采纳,获得10
3秒前
大模型的应助被笙笙采纳,获得10
3秒前
难过丹寒发布了新的文献求助10
4秒前
余念难安发布了新的文献求助10
5秒前
lele完成签到,获得积分10
5秒前
奶味蓝发布了新的文献求助20
5秒前
5秒前
7秒前
8秒前
DW的应助被西陆采纳,获得10
9秒前
10秒前
李健的小迷弟的应助被晓晓采纳,获得10
10秒前
nwds发布了新的文献求助10
10秒前
任性小霜发布了新的文献求助10
10秒前
三分之二发布了新的文献求助10
11秒前
11秒前
稳重的闭月完成签到,获得积分10
12秒前
crush完成签到,获得积分20
12秒前
郑丽琴发布了新的文献求助10
13秒前
科研通AI6.3的应助被1900采纳,获得10
14秒前
14秒前
14秒前
尉迟姿完成签到,获得积分10
14秒前
共享精神的应助被激昂的如柏采纳,获得10
14秒前
16秒前
16秒前
挚友发布了新的文献求助10
18秒前
18秒前
19秒前
希望天下0贩的0的应助被tt采纳,获得10
19秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8177767
求助须知:如何正确求助?哪些是违规求助? 9568590
关于积分的说明 21799821
捐赠科研通 7772374
什么是DOI,文献DOI怎么找? 3432476
关于科研通互助平台的介绍 2556695
邀请新用户注册赠送积分活动 2478034